Trabectedin in Cancers : Mechanisms and Clinical Applications
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Trabectedin, a tetrahydroisoquinoline alkaloid, is the first marine antineoplastic agent approved with special anticancer mechanisms involving DNA binding, DNA repair pathways, transcription regulation and regulation of the tumor microenvironment. It has favorable clinical applications, especially for the treatment of patients with advanced soft tissue sarcoma, who failed in anthracyclines and ifosfamide therapy or could not receive these agents. Currently, trabectedin monotherapy regimen and regimens of combined therapy with other agents are both widely used for the treatment of malignancies, including soft tissue sarcomas, ovarian cancer, breast cancer, and non-small-cell lung cancer. In this review, we have summarized the basic information and some updated knowledge on trabectedin, including its molecular structure, metabolism in various cancers, pharmaceutical mechanisms, clinical applications, drug combination, and adverse reactions, along with prospects of its possibly more optimal use in cancer treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - 28(2022), 24 vom: 26., Seite 1949-1965 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Jiali [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.09.2022 Date Revised 22.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1381612828666220526125806 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341415839 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341415839 | ||
| 003 | DE-627 | ||
| 005 | 20231226011730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1381612828666220526125806 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1138.xml |
| 035 | |a (DE-627)NLM341415839 | ||
| 035 | |a (NLM)35619256 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Jiali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trabectedin in Cancers |b Mechanisms and Clinical Applications |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2022 | ||
| 500 | |a Date Revised 22.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Trabectedin, a tetrahydroisoquinoline alkaloid, is the first marine antineoplastic agent approved with special anticancer mechanisms involving DNA binding, DNA repair pathways, transcription regulation and regulation of the tumor microenvironment. It has favorable clinical applications, especially for the treatment of patients with advanced soft tissue sarcoma, who failed in anthracyclines and ifosfamide therapy or could not receive these agents. Currently, trabectedin monotherapy regimen and regimens of combined therapy with other agents are both widely used for the treatment of malignancies, including soft tissue sarcomas, ovarian cancer, breast cancer, and non-small-cell lung cancer. In this review, we have summarized the basic information and some updated knowledge on trabectedin, including its molecular structure, metabolism in various cancers, pharmaceutical mechanisms, clinical applications, drug combination, and adverse reactions, along with prospects of its possibly more optimal use in cancer treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Trabectedin | |
| 650 | 4 | |a anticancer | |
| 650 | 4 | |a antineoplastic agent | |
| 650 | 4 | |a combined drug use | |
| 650 | 4 | |a malignancies | |
| 650 | 4 | |a tissue sarcomas | |
| 650 | 4 | |a tumor microenvironment | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Alkylating |2 NLM | |
| 650 | 7 | |a Dioxoles |2 NLM | |
| 650 | 7 | |a Trabectedin |2 NLM | |
| 650 | 7 | |a ID0YZQ2TCP |2 NLM | |
| 700 | 1 | |a Wang, Pengfei |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Zheng |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Caiji |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yiru |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Danli |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Wenqing |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Wenwen |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Lingjie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wenxue |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yongwei |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Zixiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yufan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Huidi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shu-Lin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d 1998 |g 28(2022), 24 vom: 26., Seite 1949-1965 |w (DE-627)NLM095430172 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:24 |g day:26 |g pages:1949-1965 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1381612828666220526125806 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 24 |b 26 |h 1949-1965 | ||